ISU App Index, ISU305 New Zealand and Australia Phase 1 Clinical Trial Completed
[Asia Economy Reporter Geum Bo-ryeong] ISU Abxis announced on the 19th that it has completed Phase 1 clinical trials of the Soliris biosimilar 'ISU305' in New Zealand and Australia.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
ISU Abxis stated, "Pharmacokinetic results demonstrated biological equivalence between ISU305 and Soliris," and added, "Pharmacodynamic results also confirmed equivalence between ISU305 and Soliris."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
